Core Viewpoint - The report highlights the AH premium rates of various companies, indicating significant discrepancies between their H-shares and A-shares, with some companies showing extremely high premiums while others exhibit negative premiums [1]. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 831.03%, with H-share priced at 0.290 HKD and A-share at 2.25 CNY [1]. - Sinopec Oilfield Service (01033) follows with a premium rate of 296.70%, H-share at 0.910 HKD and A-share at 3.01 CNY [1]. - Beijing Jingcheng Machinery Electric (00187) ranks third with a premium of 285.05%, H-share at 4.280 HKD and A-share at 13.76 CNY [1]. Group 2: Lowest AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -13.27%, with H-share priced at 511.000 HKD and A-share at 370 CNY [1]. - China Merchants Bank (03968) shows a premium of -4.06%, H-share at 49.300 HKD and A-share at 39.49 CNY [1]. - WuXi AppTec (02359) has a premium of -2.14%, with H-share at 120.800 HKD and A-share at 98.7 CNY [1]. Group 3: Top Deviation Values - Jinju Group (02009) has the highest deviation value at 24.42%, with a premium of 212.05% [1]. - Beijing Jingcheng Machinery Electric (00187) has a deviation value of 21.92%, with a premium of 285.05% [1]. - Longpan Technology (02465) ranks third with a deviation value of 19.68%, and a premium of 101.01% [1]. Group 4: Lowest Deviation Values - JunDa Co., Ltd. (02865) has the lowest deviation value at -70.56%, with a premium of 176.15% [2]. - Changfei Optical Fiber (06869) follows with a deviation of -45.38%, and a premium of 105.94% [2]. - Chenming Paper (01812) has a deviation of -26.81%, with a premium of 190.80% [2].

Core Viewpoint - ByteDance's AI video generation model Seedance 2.0 has gained significant attention both domestically and internationally, leading to a surge in AI application themes in the A-share market [1][4]. Market Overview - On February 10, the A-share market exhibited a fluctuating trend with noticeable structural differentiation. AI application themes saw widespread increases, particularly in sectors such as short drama games, cultural media, online games, virtual humans, and cybersecurity, while the photovoltaic industry experienced a pullback [1]. - The Shanghai Composite Index closed at 4122.34, down 0.02%, and the Shenzhen Component Index closed at 14206.26, also down 0.02% [2]. Cultural Media Sector - The cultural media sector experienced a significant surge, with multiple stocks hitting the 20% limit up, including Readkey Culture, Jiecheng Co., Rongxin Culture, Light Media, and Chinese Online. Other stocks like Happiness Blue Sea rose over 10% [4][5]. - The cultural media index rose by 6.76%, indicating strong market performance [5]. AI Video Technology Impact - Seedance 2.0 is expected to lead the way in the short content field, such as AI comic dramas and short dramas, by significantly reducing production costs and shortening production cycles. This advancement is anticipated to drive industry capacity expansion [6]. - The model's capabilities include self-storyboarding, multi-modal references, audio-visual synchronization, and multi-camera narrative capabilities, which are expected to enhance video usability and lower production costs [6]. Gaming Sector Performance - The gaming sector also saw widespread gains on February 10, with stocks like Wento Holdings and Perfect World reaching their daily limits [8]. - The gaming index increased by 4.71%, reflecting positive market sentiment [9]. Regulatory Environment and Market Growth - In January 2026, 182 game licenses were issued, continuing a trend of normalized issuance since 2025, indicating regulatory support for the industry's healthy development. The gaming market's actual sales revenue is projected to reach 350.79 billion yuan in 2025, marking a 7.68% year-on-year growth [9][10]. - The gaming sector is expected to benefit from AI applications, with both established and new games leveraging AI to enhance user engagement and content creation [10]. Hong Kong Market Trends - The Hong Kong market mirrored the A-share surge, particularly in cultural media and innovative drug services, with notable gains in stocks like WuXi Biologics and WuXi AppTec [11].

Group 1 - The core viewpoint of the article highlights the significant rise in the stock prices of CRO (Contract Research Organization) concept stocks in the Hong Kong market on February 10 [1] Group 2 - Viatris (01873.HK) saw an increase of 6.14%, reaching HKD 2.42 [1] - WuXi Biologics (02269.HK) rose by 6.01%, with a stock price of HKD 40.54 [1] - Tigermed (03347.HK) experienced a 4.65% increase, trading at HKD 56.3 [1] - WuXi AppTec (02359.HK) grew by 4.31%, with shares priced at HKD 121 [1]

Group 1 - CRO concept stocks have shown significant gains, with Weiya Bio rising by 6.14% to HKD 2.42, WuXi Biologics increasing by 6.01% to HKD 40.54, Tigermed up by 4.65% to HKD 56.3, and WuXi AppTec rising by 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's net profit is projected to grow by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that the CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend as innovative drug development heats up [1]

Group 1 - CRO concept stocks have shown significant gains, with companies like Viatris (01873) up 6.14% to HKD 2.42, WuXi Biologics (02269) up 6.01% to HKD 40.54, Tigermed (03347) up 4.65% to HKD 56.3, and WuXi AppTec (02359) up 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's is projected to rise by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend due to the booming innovative drug development [1]

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a strong rally on February 10, with several companies seeing significant stock price increases [1] - Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rose by over 3% [1] - Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) each saw their stock prices increase by more than 2.5% [1]

Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant discrepancies between H-shares and A-shares [1] Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 831.03%, with H-share priced at 0.290 HKD and A-share at 2.25 CNY [1] - Zhejiang Shibao (01057) follows with a premium rate of 347.33%, H-share at 5.810 HKD and A-share at 21.7 CNY [1] - Sinopec Oilfield Service (01033) ranks third with a premium rate of 304.44%, H-share at 0.900 HKD and A-share at 3.04 CNY [1] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -13.97%, with H-share priced at 513.500 HKD and A-share at 368.82 CNY [1] - China Merchants Bank (03968) has a premium rate of -3.80%, H-share at 49.220 HKD and A-share at 39.53 CNY [1] - Heng Rui Medicine (01276) shows a minimal premium rate of -0.35%, with H-share at 69.050 HKD and A-share at 57.45 CNY [1] Group 3: Top Deviation Values - Sinopec Oilfield Service (01033) leads in deviation value at 26.29%, indicating a significant difference from its average premium rate [1] - Beijing Jingcheng Machinery Electric (00187) has a deviation value of 22.66% [1] - Longpan Technology (02465) ranks third with a deviation value of 19.24% [1] Group 4: Bottom Deviation Values - Junda Co., Ltd. (02865) has the lowest deviation value at -66.46%, indicating a substantial drop from its average premium rate [1] - Zhejiang Shibao (01057) follows with a deviation value of -42.67% [1] - Yangtze Optical Fibre and Cable (06869) shows a deviation value of -33.26% [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

Core Viewpoint - Multiple A-share pharmaceutical companies have announced their 2025 performance forecasts, with 160 stocks expected to see year-on-year growth in net profit attributable to shareholders, particularly within the CXO sector, which shows robust performance and is anticipated to recover overall due to a more favorable external environment and a rebound in investment and financing [1][7]. Group 1: Company Performance - WuXi AppTec (603259.SH/2359.HK) is expected to lead in performance growth, forecasting a net profit attributable to shareholders of 19.151 billion yuan, with a non-recurring net profit of 13.241 billion yuan, reflecting a year-on-year increase of 32.6%, surpassing historical peaks [1][8]. - The company has raised its full-year revenue guidance twice in 2025, now projecting total revenue of approximately 45.456 billion yuan, a year-on-year increase of about 15.84%, with sustainable business revenue expected to grow by approximately 21.4% [2][9]. Group 2: Business Model and Growth Drivers - The unique value of WuXi AppTec's "integrated, end-to-end" CRDMO business model has significantly contributed to its performance, with over 430,000 compounds delivered in the drug discovery phase and 621 new molecules entering the D&M pipeline in 2025 [2][9]. - The number of small molecule drugs in Phase III and commercialization has increased from 107 to 167 from 2022 to the third quarter of 2025, representing a 56% year-on-year growth, with corresponding revenue growth exceeding 150% [4][11]. Group 3: Shareholder Returns - WuXi AppTec has emphasized sharing its growth with shareholders, having returned nearly 20 billion yuan through cash dividends and share buybacks over seven years, accounting for over 40% of cumulative net profit [6][14]. - Based on a 30% cash dividend policy and the 2025 performance forecast, the cash dividend amount is expected to double year-on-year, enhancing shareholder returns [6][14].